Morgan Stanley reiterated their equal weight rating on shares of AstraZeneca (LON:AZN) in a research report report published on Friday. Morgan Stanley currently has a GBX 5,000 ($66.96) target price on the biopharmaceutical company’s stock.

Several other analysts have also recently weighed in on the stock. Citigroup reaffirmed a buy rating on shares of AstraZeneca in a report on Thursday, September 7th. Barclays set a GBX 6,300 ($84.37) target price on shares of AstraZeneca and gave the company a buy rating in a report on Wednesday, September 13th. Goldman Sachs Group reaffirmed a sell rating and issued a GBX 3,800 ($50.89) target price on shares of AstraZeneca in a report on Tuesday, October 17th. Liberum Capital reaffirmed a buy rating and issued a GBX 4,800 ($64.28) target price on shares of AstraZeneca in a report on Tuesday, September 5th. Finally, Natixis raised shares of AstraZeneca from a neutral rating to a buy rating and raised their target price for the company from GBX 5,000 ($66.96) to GBX 5,738 ($76.84) in a report on Wednesday, September 6th. Four research analysts have rated the stock with a sell rating, seven have issued a hold rating and twelve have issued a buy rating to the company’s stock. The stock currently has an average rating of Hold and a consensus target price of GBX 5,164.45 ($69.16).

Shares of AstraZeneca (LON AZN) traded up GBX 3.36 ($0.04) during trading hours on Friday, reaching GBX 4,780.36 ($64.02). 1,860,000 shares of the company traded hands, compared to its average volume of 2,180,000. AstraZeneca has a 52-week low of GBX 3,996 ($53.52) and a 52-week high of GBX 5,520 ($73.93).

TRADEMARK VIOLATION NOTICE: “AstraZeneca (AZN) Receives “Equal weight” Rating from Morgan Stanley” was first posted by Daily Political and is the property of of Daily Political. If you are viewing this piece on another website, it was illegally stolen and reposted in violation of U.S. & international copyright legislation. The original version of this piece can be viewed at https://www.dailypolitical.com/2017/12/02/astrazeneca-azn-receives-equal-weight-rating-from-morgan-stanley.html.

AstraZeneca Company Profile

AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.

Analyst Recommendations for AstraZeneca (LON:AZN)

Receive News & Ratings for AstraZeneca PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca PLC and related companies with MarketBeat.com's FREE daily email newsletter.